[{"id":"3d58d724-7b7a-4521-94a7-0e3dc4880d42","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054374","created_at":"2021-09-23T17:53:02.260Z","updated_at":"2025-02-25T15:35:18.664Z","phase":"Phase 1/2","brief_title":"A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05054374","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124","tags":["HER-2 • ER • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • MAP2K1 mutation • MAP2K1 P124L • MAP2K1 P124S • MAP2K2 mutation • MAP2K1 C121S • MAP2K1 F53L • MAP2K1 K57N • MAP2K1 P124"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2024-07-09"},{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"69112ba3-2ae8-4897-864e-b49a99d79bf1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03771404","created_at":"2021-01-18T18:39:31.761Z","updated_at":"2024-07-02T16:37:04.768Z","phase":"","brief_title":"NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"","source_id_and_acronym":"NCT03771404","lead_sponsor":"Hellenic Oncology Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • TP53 • PIK3CA • NRAS • PTEN • FGFR1 • MAP2K1 • AKT1 • SOX2 • DDR2 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation • PTEN mutation • MAP2K1 mutation • AKT1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 01/05/2018","start_date":" 01/05/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-12-11"}]